Literature DB >> 27588186

Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report.

Maria Helena Ornellas1, Monique De França Silva2, Cristiana Solza3, Stella Beatriz Sampaio De Lucena Gonçalves3, Liliane Silva De Almeida1, Jackline De Paula Ayres-Silva4, Taís Leite Seixas5, Elenice Ferreira Bastos6, Thomas Liehr7, Gilda Alves8.   

Abstract

Myelodysplastic syndrome (MDS) cases comprise a heterogeneous group of hematological disorders that are characterized by impaired hematopoiesis, with cytopenias of different grades and risk of developing acute myeloid leukemia. MDS may rarely be associated with thrombocytosis. In such cases, myelodysplasia and myeloproliferative disorders may overlap, making correct diagnosis difficult. We herein describe a case of MDS with thrombocytosis, Janus kinase 2 gene mutation-positive and Perls' staining-negative, which was initially classified as essential thrombocythemia (ET). This case highlights that MDS may be misdiagnosed as ET and inappropriate treatment may be initiated. Therefore, it is crucial to carefully combine all available data on morphology and immunophenotyping, and to perform the necessary molecular, cytogenetic and molecular cytogenetic analyses, in order to correctly diagnose this disease.

Entities:  

Keywords:  Janus kinase 2 gene; aging; complex karyotype; essential thrombocythemia; myelodysplastic syndrome

Year:  2016        PMID: 27588186      PMCID: PMC4997974          DOI: 10.3892/mco.2016.947

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  23 in total

1.  Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Authors:  Sabine Jeromin; Torsten Haferlach; Sandra Weissmann; Manja Meggendorfer; Christiane Eder; Niroshan Nadarajah; Tamara Alpermann; Alexander Kohlmann; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

Review 2.  Refractory anemia with ring sideroblasts.

Authors:  Luca Malcovati; Mario Cazzola
Journal:  Best Pract Res Clin Haematol       Date:  2013-10-01       Impact factor: 3.020

3.  Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P Fenaux; D Haase; G F Sanz; V Santini; C Buske
Journal:  Ann Oncol       Date:  2014-07-25       Impact factor: 32.976

Review 4.  Refractory anemia with ring sideroblasts and RARS with thrombocytosis.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2015-06       Impact factor: 10.047

5.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 6.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

Authors:  S Murphy; P Peterson; H Iland; J Laszlo
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

7.  Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Authors:  Hadrian Szpurka; Ramon Tiu; Gurunathan Murugesan; Samer Aboudola; Eric D Hsi; Karl S Theil; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

Review 8.  Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.

Authors:  Victor Moyo; Patrick Lefebvre; Mei Sheng Duh; Behin Yektashenas; Suneel Mundle
Journal:  Ann Hematol       Date:  2008-03-20       Impact factor: 3.673

9.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Authors:  Detlef Haase; Ulrich Germing; Julie Schanz; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Andrea Kundgen; Michael Lübbert; Regina Kunzmann; Aristoteles A N Giagounidis; Carlo Aul; Lorenz Trümper; Otto Krieger; Reinhard Stauder; Thomas H Müller; Friedrich Wimazal; Peter Valent; Christa Fonatsch; Christian Steidl
Journal:  Blood       Date:  2007-08-28       Impact factor: 22.113

Review 10.  How we treat lower-risk myelodysplastic syndromes.

Authors:  Pierre Fenaux; Lionel Adès
Journal:  Blood       Date:  2013-04-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.